目的 观察依达拉奉对急性脑出血患者血清S-100β水平的影响,并进行临床疗效评定.方法 72例急性脑出血患者随机分为2组,每组36 例,对照组采用常规治疗方法 ,治疗组在对照组的基础上予以依达拉奉30 mg+生理盐水100 ml静脉滴注,每日2次,连用14 d;2组患者治疗前及治疗后2周、4周时均进行临床神经功能缺损程度评分,并应用 ELISA法测定患者发病1、3、7、14 d血清S-100β水平.结果 2组患者治疗后2周及4周临床疗效及神经功能缺损评分均有明显改善,且治疗组明显优于对照组(P<0.05).2组患者血清S-100β水平在第1天达到高峰,其后逐渐降低,差异有统计学意义(P<0.01).治疗组第3天、7天S-100β水平明显低于对照组,差异有统计学意义(P<0.05),而第14天时差异无统计学意义(P>0.05).结论 应用依达拉奉治疗急性脑出血有较好的疗效,可降低血清S-100β水平,改善神经功能缺损评分.%Objective To investigate the clinical efficacy of edaravone and serum S-100β in patients with acute intracerebral hemorrhage( ICH ).Methods 72 cases of acute intracerebral hemorrhage within 1d of onset were enrolled, they were randomly divided into the therapy group and control group.The routine treatment was used in the control group.Edaravone was infused at a dose of 30 mg, twice a day, for 14 days in the therapy group.Before treatment and at 2nd and 4th week after treatment, the neurological deficits and the clinical efficacy were evaluated.We serially( at days 1, 3, 7 and 14 ) measured the serum levels of S-100β in 72 patients.S-100β levels were measured by standard quantitative sandwich ELISA.Results There was a significant improvement of the outcome of neurological deficits score and the clinical efficacy in the two groups, but the neurological deficits score was significantly lower in the therapy group than that of the control group( P ＜ 0.05 ).For ICH, peak values of S-100β were found at 24 h, then decreased gradually( P ＜ 0.05 ).S-100β in the therapy group is lower than control group at 3d and 7d( P ＜ 0.05 ), but no difference was found at 14d( P ＞ 0.05 ).Conclusion Edaravone is effective for ICH, which can reduce the level of S-100β, improve neurological deficits score.
展开▼
